STOCKHOLM, March 15, 2021 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401), which were presented by the company and its partner Eisai at the 15th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, AD/PD. The presentations included findings suggesting that lecanemab could be of potential benefit for adults with Down's syndrome with signs of functional or cognitive deterioration. Preliminary results presented from the ongoing open-label extension of the Phase 2b study in early Alzheimer's disease continue to support the effect of lecanemab on brain amyloid levels.
BioArctic presented data that confirmed that similar to adults with Alzheimer's disease, individuals with Down's syndrome with dementia show significantly elevated levels of soluble amyloid-beta (Aß) aggregates, so called protofibrils, compared to control groups. The presentation also demonstrated for the first time that lecanemab binds to these Aß aggregates and Aß plaques in this Down's syndrome population with dementia. These combined findings suggest that targeting toxic soluble Aß aggregates with lecanemab could help preserve brain function in adults with Down's syndrome with dementia.
Eisai presented updated results from subjects who participated in the amyloid imaging sub studies in both the Core and the ongoing open-label extension of the Phase 2b study of lecanemab in early Alzheimer's disease. The results showed that the effects of lecanemab on reducing amyloid in the brain on average persist for at least two years following discontinuation of lecanemab dosing. In participants who were treated with placebo in the core study and started on 10 mg/kg biweekly lecanemab in the open label extension, showed rapid reduction in brain amyloid levels as early as three months of lecanemab treatment, with continued reduction over 12 months of treatment. Lecanemab, dosed at 10 mg/kg biweekly, was also shown to reduce brain amyloid to negative levels1 in more than 80 percent of patients who participated in the core and open-label extension study, as early as 12 months into treatment.
"The latest data further support the effects of lecanemab, and I'm encouraged to see the continued progress of both Eisai's broad ongoing clinical trial programs in Alzheimer's disease, as well as our own research related to Down's syndrome. We look forward to the continued development of lecanemab as a potential disease-modifying treatment," said BioArctic's CEO Gunilla Osswald.
BioArctic's poster as well as Eisai's presentation from the AD/PD conference, which were presented virtually as a consequence of the COVID-19 pandemic, are available on www.bioarctic.com.
1 The patient does no longer show Alzheimer's disease pathology regarding amyloid levels in the brain
This information was submitted for publication at 08:00 a.m. CET on March 15, 2021.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
For further information, please contact:
Gunilla Osswald, CEO
Phone: +46 8 695 69 30
Oskar Bosson, Vice President Communications and Investor Relations
Phone: +46 70 410 71 80
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021